Press Contact: Kirsten Mabry | (617) 495-4157
Tag: Blavatnik Biomedical Accelerator
March 9th, 2026
A research team led by Christina Woo, professor of chemistry and chemical biology, in collaboration with a team of scientists at pharmaceutical company GSK and Scripps Research Institute, discovered a hidden binding pocket on the protein cereblon. The discovery of the allosteric cereblon binder could uncover a new area of cereblon biology to explore for cancer drugs.
March 2nd, 2026
Researchers in Andrew Kruse’s lab overcame a key obstacle in using the hormone relaxin as a therapy for heart disease. With support from Harvard’s Blavatnik Biomedical Accelerator, this discovery led to the launch of Tectonic Therapeutic, which is now testing its relaxin-based drug in clinical trials.
September 25th, 2025
10 new technologies tackling urgent challenges from autoimmune disease to cancer win funding from Blavatnik Biomedical Accelerator.
June 16th, 2025
A lab at Harvard T.H. Chan School of Public Health received industry-sponsored research and aims to translate discoveries about a protein that helps regulate metabolism and inflammation into novel therapeutics for obesity, heart disease, and age-related illnesses.
June 12th, 2025
Video on how OTD supports Harvard’s mission to bring innovation out of labs to make a real-world impact.
